Expertise in
4
conditions

Dr. Burton E. Appel

Pediatric Hematology Oncology
Children's Cancer Institute
61 Davis Avenue, Suite 1, 
Neptune, NJ 
Clinical Trials:Currently Recruiting for 3 Trials
Accepting New Patients
Referral may be required
Before you request
Expertise in
4
conditions
Children's Cancer Institute
61 Davis Avenue, Suite 1, 
Neptune, NJ 

Overview

Burton Appel is a Pediatric Hematologist Oncology provider practicing medicine in Neptune, New Jersey.

Dr. Appel is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL), Hodgkin Lymphoma, Acute Lymphoblastic Leukemia (ALL), Leukemia, and Bone Marrow Aspiration.

Dr. Appel is board certified in American Board Of Pediatrics and American Board Of Pediatrics . He is actively involved in clinical research, co-authoring 24 peer reviewed articles and participating in 40 clinical trials. Dr. Appel is currently accepting new patients.

Graduate Institution

University Of Chicago Pritzker School Of Medicine

Specialties

Pediatric Hematology Oncology

Licenses

Pediatric Hematology-Oncology in NJ

Board Certifications

American Board Of Pediatrics
American Board Of Pediatrics

Fellowships

University of Chicago Comer Childrens Hospital

Languages Spoken

English
Hebrew

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

Children's Cancer Institute
61 Davis Avenue, Suite 1, Neptune, NJ 7753.
Other Locations
Hackensack University Medical Center
30 Prospect Avenue, Pediatric Blood And Marrow Transplant, Hackensack, NJ 7601.

Additional Areas of Focus

Dr. Appel has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

40 Clinical Trials

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Calaspargase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Inotuzumab, Leucovorin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Thioguanine, Vincristine
Study Phase: Phase 3
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Busulfan, Carboplatin, Cisplatin, Crizotinib, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Etoposide Phosphate, Isotretinoin, Melphalan Hydrochloride, Sargramostim, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate
Study Phase: Phase 3
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, Filgrastim, Nivolumab, Pegfilgrastim, Prednisolone, Prednisone, Rituximab, Rituximab+Hyaluronidase Human, Vincristine Sulfate
Study Phase: Phase 3
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Procedure, Other, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Other
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine
Study Phase: Phase 3
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Enrollment Status: Completed
Publish Date: July 31, 2026
Intervention Type: Drug, Behavioral, Other, Procedure
Study Drug: 6-Mercaptopurine
Study Phase: Phase 3
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2026
Intervention Type: Drug, Biological, Radiation
Study Drugs: Erwinia Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2026
Intervention Type: Drug, Procedure, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Inotuzumab, Leucovorin, 6-Mercaptopurine, Pegaspargase, Vincristine
Study Phase: Phase 2
View 7 Less Clinical Trials

24 Total Publications

Journey to a Fertility Preservation Program: For the Next Generation.
Journey to a Fertility Preservation Program: For the Next Generation.
Journal: Pediatric blood & cancer
Published: April 07, 2026
Similar Doctors
Expertise in
9
conditions
Dr. Banu Aygun
Pediatric Hematology Oncology
Expertise in
9
conditions
Dr. Banu Aygun
Pediatric Hematology Oncology
Referral may be required
Before you request

Northwell Health Pediatric Hematology/Oncology & Stem Cell Transplant

269-01 76th Avenue, Suite 255, 
New Hyde Park, NY 
 (41.8 miles away)
718-470-3460
Languages Spoken:
English, Turkish
See accepted insurances
Accepting New Patients

Banu Aygun is a Pediatric Hematologist Oncology provider practicing medicine in New Hyde Park, New York. Dr. Aygun is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Splenectomy. Dr. Aygun is currently accepting new patients.

Expertise in
7
conditions
Dr. Jeffrey M. Lipton
Pediatric Hematology Oncology
Expertise in
7
conditions
Dr. Jeffrey M. Lipton
Pediatric Hematology Oncology
Referral may be required
Before you request

Northwell Health Pediatric Hematology/Oncology & Stem Cell Transplant

269-01 76th Avenue, Suite 255, 
New Hyde Park, NY 
 (41.8 miles away)
718-470-3460
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jeffrey Lipton is a Pediatric Hematologist Oncology provider practicing medicine in New Hyde Park, New York. Dr. Lipton is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Aase Syndrome, Pure Red Cell Aplasia, Transient Erythroblastopenia of Childhood, Aplastic Anemia, and Bone Marrow Transplant. Dr. Lipton is board certified in American Board Of Pediatrics. Dr. Lipton is currently accepting new patients.

Expertise in
6
conditions
Dr. James B. Bussel
Pediatric Hematology Oncology
Expertise in
6
conditions
Dr. James B. Bussel
Pediatric Hematology Oncology
Referral may be required
525 E 68th St # P-695, 
New York, NY 
 (39.2 miles away)
212-746-3400
Languages Spoken:
English
See accepted insurances

James Bussel is a Pediatric Hematologist Oncology provider practicing medicine in New York, New York. Dr. Bussel is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Immune Thrombocytopenic Purpura (ITP), Blood Clots, Anemia, Evans Syndrome, and Splenectomy.

Frequently Asked Questions about Dr. Burton E. Appel

How do I make an appointment with Dr. Burton E. Appel?

You can book an appointment with Dr. Burton E. Appel by calling their office at 732-776-4860. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Burton E. Appel a top-rated expert for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Burton E. Appel is classified as an Advanced expert for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Burton E. Appel specialize in?

While Dr. Burton E. Appel is a Pediatric Hematology Oncology, they have specific expertise in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL), Hodgkin Lymphoma, and Acute Lymphoblastic Leukemia (ALL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatric Hematology Oncology.

Does Dr. Burton E. Appel participate in research or clinical trials?

Yes. Dr. Burton E. Appel has published 24 articles and abstracts on conditions like Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). You can view a list of Dr. Burton E. Appel's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Burton E. Appel accept my insurance?

Dr. Burton E. Appel accepts most major insurance plans, including Cigna and Horizon Healthcare. We recommend calling the office directly at 732-776-4860 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Appel's expertise for a condition
ConditionClose
      View All 15 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile